Raymond James raises Regeneron stock price target to $1,020 on strong quarter

Raymond James raised its Regeneron price target to $1,020 from an undisclosed prior level and maintained an Outperform rating, citing strong Q3 2026 results and pipeline catalysts. Regeneron reported adjusted EPS of $20.07 and revenue of $5.12 billion, up 70% and 36% year over year, respectively; Dupixent generated record global sales of $6.5 billion. Raymond James sees cash rising from $16.2 billion in Q3 2026 to approximately $26 billion by year-end 2027, while upcoming clinical and product milestones may support further growth.

Analysis

The key question is whether Regeneron can convert a strong commercial base into durable, internally funded pipeline growth—not whether one quarter beat estimates. The reported beat and analyst revisions may already have raised the bar; the $1,020 target is only one analyst’s scenario, while Baird’s Neutral stance underscores that strong execution need not mean near-term multiple expansion. Treat platform fair-value estimates as model outputs, not independent validation.

Over the next 1–3 months, CIDEB MASH and pivotal PNH data are the most consequential binary catalysts; cemdisiran’s launch potential and an Eylea HD prefilled-syringe decision are more execution/regulatory tests. Positive outcomes could support incremental pipeline value, but a miss or delay could quickly unwind catalyst premium. Eylea’s durability also faces substitution pressure from Roche’s Vabysmo and biosimilar competition over time. Dupixent strength is a shared commercial driver for Regeneron and Sanofi, so it is not a clean REGN-only advantage.

Over 6–18 months, projected cash accumulation could expand Regeneron’s strategic flexibility, but any business-development push introduces asset-selection and integration risk; cash conversion and deal returns matter more than the cash balance alone. Verify what the end of Sanofi development reimbursement means for recurring cash flows before capitalizing the projected acceleration. The contrarian risk is that investors extrapolate an unusually strong quarter and pipeline optionality while underweighting trial failure, Eylea erosion, and the possibility that cash is deployed at poor returns.

Key Decisions for Investors

• Do not chase the earnings beat solely on the $1,020 target. Consider a modest REGN long on weakness or ahead of a clearly scheduled catalyst only if position sizing reflects binary clinical risk; no option structure is justified without event timing and implied-volatility data.
• Track CIDEB MASH and PNH readouts, cemdisiran launch progress, and the Eylea HD syringe regulatory decision. Reassess promptly on adverse data, a material delay, or weaker-than-expected commercial uptake.
• Verify quarterly free-cash-flow conversion, the accounting/economic effect of ended Sanofi development reimbursement, and management’s capital-allocation plans. The cash-build thesis weakens if cash generation misses the trajectory or acquisitions dilute returns.
• Falsifiers: deterioration in Dupixent growth, renewed Eylea erosion versus competing therapies, pipeline setbacks, or guidance that fails to sustain the post-beat earnings outlook. Sanofi is a related beneficiary through Dupixent, but a REGN/SNY pair is not a clean expression of the catalyst thesis.